Sage Therapeutics Inc (SAGE)

Add to Watchlists
Create an Alert
Quickflows
76.61 -0.53  -0.69% NASDAQ Apr 9, 20:00 USD
View Full Chart
Price Chart
View All Key Stats

Key Stats

View All SAGE News

News

View All Events

Events

Date Type Description
05/07/2020 16:30 EDT Earnings Calls Q1 2020 Earnings Call
05/07/2020 00:00 Earnings Results Q1 2020 Earnings Results
06/09/2020 09:00 EDT Agm 2019 Annual General Meeting
08/10/2020 08:30 EDT Earnings Calls Q2 2020 Earnings Call
08/10/2020 00:00 Earnings Results Q2 2020 Earnings Results
11/05/2020 00:00 Earnings Results Q3 2020 Earnings Results
11/05/2020 08:30 EST Earnings Calls Q3 2020 Earnings Call
02/24/2021 00:00 Earnings Results Q4 2020 Earnings Results
02/24/2021 08:00 EST Earnings Calls Q4 2020 Earnings Call
05/07/2021 16:30 Earnings Results Q1 2021 Earnings Results
View All Performance Charts

Total Returns Comparison

Fundamentals

Income Statement View Statement

Revenue (TTM) 1.114B
Total Expenses (TTM) 490.23M
Net Income (TTM) 606.07M

Balance Sheet View Statement

Total Assets (Quarterly) 2.159B
Total Liabilities (Quarterly) 86.91M
Shareholders Equity (Quarterly) 2.072B

Cash Flow Statement View Statement

Cash from Operations (TTM) 664.28M
Cash from Investing (TTM) 442.68M
Cash from Financing (TTM) 426.76M

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.sagerx.com
  • Investor Relations URL: https://investor.sagerx.com/
  • HQ State/Province: Massachusetts
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Small Cap/Growth
  • Next Earnings Release: May. 07, 2021
  • Last Earnings Release: Feb. 24, 2021
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of the nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-217 program which is in Phase 3 clinical trials for post-partum depression, essential tremor, Parkinson's disease, and major depressive disorder. The company is also developing several other compounds for treatment that are in the early stage of development.

Analyst Coverage

Consensus Recommendations
Buy Recommendations Upgrade
Outperform Recommendations Upgrade
Hold Recommendations Upgrade
Underperform Recommendations Upgrade
Sell Recommendations Upgrade
Consensus Recommendation Upgrade
Consensus Rating Upgrade
Target Price
Price 76.61
Price Target Upgrade
Price Target Upside (Daily) Upgrade

Top Fund Holders

Symbol Name Weighting
F000015ZK6 ST Healthcare Innovations 10 F RE 3.45%
AGF489 AGF US Small-Mid Cap (USD) 2.81%
BBP Virtus LifeSci Biotech Products ETF 2.38%
MIND.TO Horizons Active A.I. Global Equity ETF 2.34%
GLRY Inspire Faithward Mid Cap Mmntm ESG ETF 1.96%
F000013KMV ST Healthcare Innovations 7 F CA 1.91%
FXH First Trust Health Care AlphaDEX® ETF 1.91%
PJHRX PGIM Jennison Health Sciences R 1.45%
IBBJ Defiance Nasdaq Junior Biotechnology ETF 1.27%
FBIOX Fidelity® Select Biotechnology 1.06%
FIJYX Fidelity Advisor® Biotechnology Z 0.93%

Comparables

Edit
BIIB Biogen Inc
IONS Ionis Pharmaceuticals Inc
MRNA Moderna Inc
ALGN Align Technology Inc
LLY Eli Lilly and Co

Other Resources

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.